The objectives of the National Center of Competence in Research (NCCR) "AntiResist" are to search for new antibiotics and to develop alternative strategies to combat antibiotic-resistant pathogens. "AntiResist" is one of a…
The Biozentrum start-up Aukera Therapeutics was selected to join the BaseLaunch Accelerator Program. With its qualification for this program, the biotech venture receives funding of up to 500,000 Swiss francs as well as…
This year, the Life Sciences Society LS2 honors the infection biologist Prof. Marek Basler from the Biozentrum, University of Basel, for his fundamental work on the structure and function of a bacterial injection apparatus -…
A number of pathogens protect themselves with an outer membrane that makes it difficult to combat them with antibiotics. In addition, the widespread use of antibiotics promotes the development of resistant bacteria. In…
The distinguished jury announced that Prof. Marek Basler from the Biozentrum, University of Basel, will receive the Sanofi-Institut Pasteur International Junior Award this year together with Prof. Ido Amit, Weizmann…
Start date is by mutual arrangement, with the possibility to start immediately How does life emerge from molecules and cells? This is the central question that motivates us. With curiosity and passion, we investigate the…
Starting immediately or upon agreement How does life emerge from molecules and cells? This is the central question that motivates us. With curiosity and passion, we investigate the entire spectrum ranging from the atom to…
Proteomics at the Biozentrum Proteomics rapidly evolves from a discovery-oriented technique to a robust and sensitive quantitative tool in biological research to study changes in protein expression and protein modifications…
Prof. Dr. Richard M. Franklin, Emeritus 1971 - 1995 | Professor of Structural Biology In 1971, Richard M. Franklin (*1930, † 2020) was appointed to the Biozentrum as one of its first professors. It was here that he began to…
According to T3 Pharmaceuticals (T3 Pharma), the funds of more than 25 million Swiss francs will be used primarily to progress the lead candidate through early clinical studies. The clinical trial in patients with solid…
This website uses cookies to collect data from users and improve functionality. By continuing to browse the site you are agreeing to this. Receive more information by reading our privacy policy.
